Patients receiving a specific type of immunotherapy for lung cancer may get an added benefit from the treatment — darker hair. Researchers at Universitat Autònoma de Barcelona in Spain tracked the color of 14 patients’ hair before and during treatment with anti–programmed cell death 1 and anti–programmed cell death ligand 1 (anti-PD1 and anti–PD-L1, respectively) therapies. Thirteen patients had diffuse darkening of the hair, while one developed black patches between white hairs. This pigmentation could be used as a marker to determine whether patients receiving anti-PD1/anti–PD-L1 therapy for lung cancer are responding well to the treatment, the scientists suggest. The results were published in JAMA Dermatology.
Read Full Article Here >>